US FDA aims to ensure citizen petitions do not improperly delay generics
This article was originally published in SRA
The US Food and Drug Administration has proposed amending its regulations to ensure that citizen petitions are not used as a tool by brand name drug companies and others to improperly delay the approval of generics and certain new drug applications submitted under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act1.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.